Senolytics: Opening avenues in drug discovery to find novel therapeutics for Parkinson's Disease.

• Parkinson's Disease (PD) affects motor functions of individual. • Accumulation of senescent cells (SC) deteriorate the pathological cascade of PD. • SC secrete components that make up the senescence-associated secretory phenotype (SASP). • Senolytics are reported to selectively kill SC via apoptosis. • Dasatinib, Quercetin, Fisetin and Navitoclax have ability to kill SC. Aging is one of the major risk factors for most neurodegenerative disorders including Parkinson's disease (PD). More than 10 million people are affected with PD worldwide. One of the predominant factors accountable for progression of PD pathology could be enhanced accumulation of senescent cells in the brain with the progress of age. Recent investigations have highlighted that senescent cells can ignite PD pathology via increased oxidative stress and neuroinflammation. Senolytics are agents that kill senescent cells. This review mainly focuses on understanding the pathological connection between senescence and PD, with emphasis on some of the recent advances made in the area of senolytics and their evolution to potential clinical candidates for future pharmaceuticals against PD. [ABSTRACT FROM AUTHOR]